Replicor宣布发布检查REP 2139抗病毒机制的新研究

齐欢畅

StephenW 发表于 2019-2-26 21:26
他们已经说结果是假的!

谁也无法定论真假。辩无胜。你懂的。

StephenW

回复 齐欢畅 的帖子

我不懂. Replicor的结果是真实的. 许多HBV医生和科学家相信Replicor的结果是真实的.

齐欢畅

StephenW 发表于 2019-2-26 21:48
回复 齐欢畅 的帖子

我不懂. Replicor的结果是真实的. 许多HBV医生和科学家相信Replicor的结果是真实的.

寓言，海洋里瓶子中的妖魔。

平凡之路123

回复 StephenW 的帖子

韩春雨的是国际期刊，一个大会的会议纪要算哪门子的期刊，不用撤稿。

REP不在本土实验，跑到孟加拉达卡，为的就是不被人指控作假啊。厉害厉害，佩服佩服。

审稿人看见这么牛逼哄哄的药物，分分钟清除表抗的药物，还不赶紧入股，实现财务自由，等什么呢。

newchinabok

StephenW 发表于 2019-2-26 21:33
回复 newchinabok 的帖子

"rep没有后续临床试验计划。" - 这是你的证据吗？你是Replicor发言人? ...

你能拿出证据吗？

StephenW

平凡之路123 发表于 2019-2-26 21:52
回复 StephenW 的帖子

韩春雨的是国际期刊，一个大会的会议纪要算哪门子的期刊，不用撤稿。

我再重复一次。以下是Replicor的国际期刊出版物2017-2019.
EASL，AASLD会议摘要在各自的国际期刊上发表.

Peer Reviewed同行评审 Publications on Replicor's NAP Technology: 2018-2017

Inhibition of HBsAg secretion by nucleic acid polymers in HepG2.2.15 cells.

Blanchet M, Sinnathamby V, Vaillant A, Labonté P. Antiviral Research 2019 epub Feb 13, 2019.

Read publication

Variants of hepatitis B virus surface antigen observed during therapy with nucleic acid polymer REP 2139-Ca have no influence on treatment outcome and its detection by diagnostic assays.

Mijočević H, Karimzadeh H, Seebach J, Usman Z, Mamun AM, Bazinet M, Vaillant A, Roggendorf M. Journal of Viral Hepatitis 2018 epub Nov 19, 2018.

Read publication

REP 2139: Antiviral Mechanisms and Applications in Achieving Functional Control of HBV and HDV Infection.

Vaillant A. ACS Infectious Diseases 2018 epub Oct 8, 2018.

Read publication

Nucleic acid polymer REP 2139 and nucleos(t)ide analogues act synergistically against chronic hepadnaviral infection in vivo.

Quinet J, Jamard C, Burtin M, Lemasson M, Guerret S, Sureau C, Vaillant A, Cova L. Hepatology 2017 epub Dec 18 2017.

Read publication

Nucleic acid polymers are active against Hepatitis Delta Virus infection in vitro.

Beilstein F, Blanchet M, Vaillant A, Sureau C. Journal of Virology 2017 epub Dec 6 2017.

Read publication

Activity of nucleic acid polymers in rodent models of HBV infection.

Schöneweis K, Motter N, Roppert PL, Lu M, Wang B, Roehl I, Glebe D, Yang D, Morrey JD, Roggendorf M, Vaillant A. Antiviral Research 2017 epub Nov 8, 2017.

Read publication

Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial

Bazinet M, Pântea V, Cebotarescu V, Cojuhari L, Jimbei P, Albrecht J, Schmid P, Le Gal F, Gordien E, Krawczyk A, Mijočević H, Karimzadeh H, Roggendorf M, Vaillant A. The Lancet Gastroenterology & Hepatology 2017 epub Sept 27, 2017.

Read publication

REP 301 study protocol

Read Publication

Inhibition of hepatitis B viral entry by nucleic acid polymers in HepaRG cells and primary human hepatocytes

Guillot C, Martel N, Berby F, Bordes I, Hantz O, Blanchet M, Sureau C, Vaillant A, Chemin I. PLOS ONE 2017 12: e0179697.

Read Publication

Nucleic Acid Polymers with Accelerated Plasma and Tissue Clearance for Chronic Hepatitis B Therapy.

Roehl I, Seiffert S, Brikh C, Quinet Q, Jamard C, Dorfler N, Lockridge JA, Cova L, Andrew Vaillant A. Mol Ther Nuc Acids. 2017 8: 1-12.

Read Publication

Nucleic acid-based polymers effective against hepatitis B Virus infection in patients don’t harbor immunostimulatory properties in primary isolated liver cells.

Real CI, Werner M, Paul A, Gerken G, Schlaak JF, Vaillant A, Broering B, Sci. Reports. 2017 7: 43838.

Read Publication

StephenW

齐欢畅 发表于 2019-2-26 21:51
寓言，海洋里瓶子中的妖魔。

科学是基于寓言? 临床试验基于寓言?

StephenW

newchinabok 发表于 2019-2-26 22:01
你能拿出证据吗？

"rep没有后续临床试验计划。" - 这些是你的话. 你拿出证据支持自己.

newchinabok

StephenW 发表于 2019-2-26 22:09
"rep没有后续临床试验计划。" - 这些是你的话. 你拿出证据支持自己.

不争了，希望成功，和而不同

fuke

希望今年进入三期